UroNav Fusion Biopsy System

technician showing screen to patient

What is a Targeted Prostate Biopsy?

A targeted prostate biopsy is an advanced diagnostic technique designed to improve the accuracy of prostate cancer detection. One of the leading technologies used for this approach is the UroNav® Fusion Biopsy system, which combines MRI imaging with real-time ultrasound to create a detailed, three-dimensional view of the prostate. This fusion of imaging allows physicians to precisely locate and sample areas that may be suspicious for cancer.

Traditional biopsies typically involve collecting tissue samples from multiple regions of the prostate in a systematic, but somewhat random, pattern. While this method can be effective, it may miss smaller or more aggressive tumors. Targeted biopsy enhances detection by focusing directly on abnormalities identified through imaging, improving both precision and diagnostic confidence.

How a UroNav Fusion Biopsy Works

A UroNav Fusion Biopsy is performed using a series of steps that combine advanced imaging with precise guidance technology.

The process begins with a multiparametric MRI, which provides detailed images of the prostate. These images allow radiologists to identify areas that may be suspicious for cancer.

During the biopsy, the MRI images are fused with real-time ultrasound using the UroNav system. This integration creates a three-dimensional map of the prostate, enabling the physician to accurately locate and track the areas identified on the MRI.

With this enhanced visualization, the physician guides the biopsy needle directly to the targeted regions and collects tissue samples for analysis. By focusing on the most suspicious areas, this approach improves the likelihood of detecting clinically significant cancer.

Why a UroNav Fusion Biopsy May Be Recommended

A physician may recommend a targeted prostate biopsy for several reasons. One common reason is elevated prostate-specific antigen (PSA) levels, which may indicate an increased risk of prostate cancer.

A UroNav Fusion Biopsy may also be recommended if:

  • A patient has persistently elevated PSA levels

  • A digital rectal exam (DRE) reveals abnormalities

  • A previous biopsy was negative or inconclusive, but suspicion for cancer remains

  • A patient with low-risk prostate cancer is undergoing active surveillance and requires careful monitoring for disease progression

In these situations, targeted biopsy technology can provide more detailed information and improve diagnostic confidence.

Benefits of a Targeted Biopsy

Targeted biopsy techniques, such as the UroNav Fusion Biopsy, offer several important advantages over traditional methods:

Enhanced cancer detection
By directly sampling areas identified as suspicious on MRI, targeted biopsies increase the likelihood of identifying clinically significant tumors.

Improved detection of aggressive disease
This approach is more effective at identifying higher-risk cancers that may be missed with standard, systematic sampling.

Greater diagnostic accuracy
More precise sampling provides clearer information, helping physicians develop more informed and personalized treatment plans.

Reduced likelihood of overtreatment
With improved accuracy, targeted biopsies help distinguish between aggressive cancers that require intervention and slower-growing cases that may be safely monitored.

A More Precise Approach to Prostate Cancer Diagnosis

The UroNav Fusion Biopsy system represents a significant advancement in prostate cancer detection. By integrating MRI imaging with real-time ultrasound guidance, this technology allows for more precise tissue sampling and clearer diagnostic insights. The result is improved accuracy in identifying clinically significant prostate cancer and more informed treatment planning.

If a prostate biopsy has been recommended, discussing targeted biopsy options such as UroNav Fusion technology can help support a more accurate diagnosis and a more confident path forward in your care.

Prostate Cancer